diabetic macular edema

Updated: December 28, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

faricimab

Regimen 1:
6mg every four weeks by intravitreal injection for the first four doses
Regimen 2:
6mg every four weeks by intravitreal injection for the first six doses

fluocinolone intravitreal implant

Initially released at rate of 0.25 mcg daily over approximately 36 months

aflibercept intravitreal

Intravitreal injection of 2 mg/0.05 ml every 4Week(monthly) for first 5 injections, after that intravitreal injection of 2 mg/0.05ml every 8Week (2 months)
May be dosed frequently with intravitreal injection of 2 mg/0.05 ml every 4Week(monthly), further efficacy was not exhibited in some patients when given dosed monthly compared to 2 months
Some patients need to be dosed intravitreal injection of 2 mg/0.05 ml every 4Week(monthly) after first 20 weeks(5months)

brolucizumab intravitreal

Administer 6 mg through intravitreal injection every six weeks (approximately 39-45 days) for the initial five doses and subsequently adjusting the dosage to 6 mg every 8-12 weeks

Future Trends